[Podcast] Closing the Distance in Cancer Care

This podcast episode explores the critical role community oncology plays in the U.S. healthcare system and why supporting its growth and autonomy matters for patients and providers.

May 13, 2026

Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

By Delilah Alvarado • May 12, 2026

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts. 

By Ben Fidler • May 12, 2026

GSK cuts deal with Sino to broaden reach of hepatitis B drug

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

By Delilah Alvarado • May 11, 2026

Biotech layoffs are easing, but is the worst over?

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

By Kelly Bilodeau • May 11, 2026

The capacity crunch in biopharma is a location problem

Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change the math on scaling.

May 11, 2026

Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies

The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.

By Marken, UPS Healthcare Precision Logistics • May 11, 2026

Lilly, Gilead lead pharma’s M&A boom

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.

By Kelly Bilodeau • May 8, 2026

Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline

Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020. 

By Delilah Alvarado • May 6, 2026

Novo hikes guidance on Wegovy pill’s fast sales start

In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.

By Kristin Jensen • May 6, 2026

Avalo shares spike on skin drug data; BioNTech to cut staff

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.

By Ben Fidler • May 6, 2026

What is your AI drug repurposing strategy missing?

Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.

By Iman Bhattacharya • May 4, 2026

Merck still sees ‘compelling’ outlook for Terns leukemia drug

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.

By Jonathan Gardner • April 30, 2026

UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. 

By Delilah Alvarado • April 30, 2026

Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.

By Kristin Jensen • April 30, 2026

Pfizer deals extend patent life for a top-selling rare disease drug

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam. 

By Ben Fidler • April 28, 2026

Boehringer dual-acting obesity shot hits mark in Phase 3 trial

Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.

By Jonathan Gardner • April 28, 2026

Sanofi MS drug rejected in US gets an endorsement in Europe

Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory approval. 

By Delilah Alvarado • April 24, 2026

Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.

By Jonathan Gardner • April 23, 2026

Sanofi posts upbeat sales as R&D pressure builds

A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.

By Kristin Jensen • April 23, 2026

An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?

A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”

By Alexandra Pecci • April 22, 2026

Merck’s fast-ascending kidney cancer drug hits a setback

Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.

By Ben Fidler • April 21, 2026

[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services

This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.

By BioPharma Dive's studioID • April 20, 2026

What actually drives speed in complex drug development programs

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

By Doug Ahrens, Program Transformation Director, Integrated Supply & Delivery, Thermo Fisher Scientific • April 20, 2026

5 notable pharma CEO pay hikes in 2025

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.”

By Alexandra Pecci • April 17, 2026